Stock ETNB 89BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

89bio, Inc. Stock

Equities

ETNB

US2825591033

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.26 USD +0.12% Intraday chart for 89bio, Inc. -9.03% -26.05%
Apr. 17 89bio, Inc. Appoints Martin Babler to Its Board of Directors CI
Apr. 03 89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing MT

Financials (USD)

Sales 2024 * 938K Sales 2025 * 2.19M Capitalization 787M
Net income 2024 * -194M Net income 2025 * -254M EV / Sales 2024 * 411 x
Net cash position 2024 * 401M Net cash position 2025 * 190M EV / Sales 2025 * 273 x
P/E ratio 2024 *
-3.73 x
P/E ratio 2025 *
-3.04 x
Employees 70
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.16%
More Fundamentals * Assessed data

Chart 89bio, Inc.

Dynamic Chart

Latest news about 89bio, Inc.

89bio, Inc. Appoints Martin Babler to Its Board of Directors CI
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Gain Wednesday Afternoon MT
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status MT
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis CI
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis CI
North American Morning Briefing : Stock Futures -2- DJ
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating MT
Top Premarket Gainers MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk MT
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk MT
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing MT
More news

Analyst Recommendations on 89bio, Inc.

89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing MT
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk MT
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk MT
More recommendations

Press releases 89bio, Inc.

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors GL
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GL
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis GL
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis AQ
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis GL
More press releases

News in other languages on 89bio, Inc.

ANALYSEN DES TAGES von Dow Jones Newswires (07.07.2023)
More news

Quotes and Performance

1 day+0.12%
1 week-9.03%
Current month-29.04%
1 month-26.25%
3 months-18.78%
6 months+20.23%
Current year-26.05%
More quotes

Highs and lows

1 week
8.04
Extreme 8.04
9.78
1 month
8.04
Extreme 8.04
11.69
Current year
7.47
Extreme 7.47
16.63
1 year
6.58
Extreme 6.575
22.93
3 years
2.00
Extreme 2
27.99
5 years
2.00
Extreme 2
47.25
10 years
2.00
Extreme 2
47.25
More quotes

Managers and Directors - 89bio, Inc.

Managers TitleAgeSince
Rohan Palekar CEO
 Chief Executive Officer 58 18-05-31
Ryan Martins DFI
 Director of Finance/CFO 47 19-06-30
Paul Shin COO
 Chief Operating Officer - 20-07-31
Members of the board TitleAgeSince
Lota Zoth BRD
 Director/Board Member 64 20-05-31
Rohan Palekar CEO
 Chief Executive Officer 58 18-05-31
Kathy LaPorte BRD
 Director/Board Member 62 21-10-31
More insiders

ETFs positioned on 89bio, Inc.

Name Weight AuM 1st Jan change Investor Rating
ADVISORSHARES DORSEY WRIGHT MICRO-CAP ETF - USD ETF AdvisorShares Dorsey Wright Micro-Cap ETF - USD
1.01% 4 M€ -5.15% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.05% 2 M€ -.--%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.05% 0 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.02% 0 M€ 0.00% -
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD ETF SPDR MSCI World Small Cap UCITS ETF - USD
0.01% 773 M€ -.--% -
More ETFs positioned on 89bio, Inc.

Quotes

Date Price Change Volume
24-04-26 8.26 +0.12% 653,066
24-04-25 8.25 -3.85% 1,012,055
24-04-24 8.58 -3.81% 871,176
24-04-23 8.92 -4.19% 745,431
24-04-22 9.31 +2.53% 580,198

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes

Company Profile

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Sector
Biotechnology & Medical Research
Calendar
2024-05-07 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.26 USD
Average target price
31.89 USD
Spread / Average Target
+286.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
89BIO, INC. Stock 89bio, Inc.
-26.05% 787M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ETNB Stock